345: Advances in diagnosing and managing osteoarthritis in dogs

The Vet Blast Podcast presented by dvm360

Sponsored by Elanco
Elise Kelly, DVM, graduated from Eastern Illinois University with a Bachelor of Sciences degree in zoology and a minor in chemistry. She earned her DVM degree from Ross University School of Veterinary Medicine, then practiced in Blue Springs, MO for 9 years before joining Elanco in 2015 as a Regional Consulting Veterinarian. In her nine years of practice, her special interests included dermatology, small exotics, and reproductive medicine, attaining a certification in canine AI in 2012. Since joining Elanco, Kelly has had the opportunity to train intensively and speak on topics including parasitology, pain management, dermatology and immunology. She has given over 500 presentations and spoken at continuing education events including Kansas City’s Frostbite and the annual Missouri Veterinary Medical Association Conference. Kelly is Fear Free Elite, compassion fatigue and Human Animal Bond certified.
She supports and works with Elanco sales representatives throughout the Midwest. She is a member of the Missouri Veterinary Medical Association and is Vice Chair for the board of directors at the Kansas City Pet Project.
She currently resides in Independence, Missouri with her husband, two children, Sheepadoodle puppy, cat, and four goats. In her spare time, you might find her cheering for the Kansas City Chiefs, boating, hiking or traveling with her family.
Indication
Galliprant controls pain and inflammation associated with osteoarthritis in dogs.
Important Safety Information
For use in dogs only. Keep this and all medications out of reach of children and pets to prevent accidental ingestion or overdose. Galliprant is a non-COX inhibiting NSAID. As a class, NSAIDs may be associated with gastrointestinal, kidney and liver side effects. Evaluation for pre-existing conditions and regular monitoring are recommended. Do not use in dogs that have a hypersensitivity to grapiprant. Concomitant use of Galliprant with other NSAIDs or corticosteroids should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. Owners should be advised to observe for signs of potential drug toxicity. Adverse reactions may include vomiting, diarrhea, decreased appetite, watery or bloody stools, and decreases in serum albumin and total protein. Click here for full prescribing information
Galliprant, Elanco, and the diagonal bar logo are trademarks of Elanco or its affiliates. ©2025 Elanco or its affiliates. PM-US-25-1504